Mental DailyMental Daily
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • My Bookmarks
Aa
Mental Daily
Aa
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • Opinion
Search
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • My Bookmarks
Follow US
  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store
© 2022 - Mental Daily. All Rights Reserved.
Clinical

New experimental treatment may boost cognitive function in fragile X syndrome

Staff Writer
Staff Writer 2 years ago
Updated 2021/05/12 at 6:18 PM
Share
SHARE

In Nature Medicine, researchers tested the use of a new experimental treatment for patients with fragile X syndrome, a known genetic causal factor of autism.

Known as BPN14770, the experimental treatment completed a phase 2 randomized, placebo-controlled trial involving 30 participants in early and mid-adulthood.

“This phase 2 trial was a 24-week randomized, placebo-controlled, two-way crossover study in 30 adult male patients (age 18–41 years) with FXS. Participants received oral doses of BPN14770 25 mg twice daily or placebo,” the study says.

“Primary outcomes were prespecified as safety and tolerability with secondary efficacy outcomes of cognitive performance, caregiver rating scales and physician rating scales.”


“Results from this study using direct, computer-based assessment of cognitive performance by adult males with FXS indicate significant cognitive improvement in domains related to language with corresponding improvement in caregiver scales rating language and daily functioning,” the study concluded.

The study was authored by Elizabeth M. Berry-Kravis, Mark D. Harnett, Scott A. Reines, Melody A. Reese, Lauren E. Ethridge, Abigail H. Outterson, Claire Michalak, Jeremiah Furman, and Mark E. Gurney.

Photo: Alamy

You Might Also Like

New study explores test that can detect Alzheimer’s years before diagnosis

New research explores the association between viral infection and Alzheimer’s disease

Prenatal exposure to pollution may be linked to lower cognitive scores in infants

Researchers unveil new drug candidate to help treat adrenoleukodystrophy

New research finds Alzheimer’s risk factors affect males and females very differently

TAGGED: Fragile X syndrome, cognition, neuroscience
Staff Writer May 2, 2021
Share this Article
Facebook Twitter Whatsapp Whatsapp Email Print
Previous Article Researchers established four subtypes of Alzheimer’s disease involving tau pathology
Next Article Social media users and conservatives were more likely to spread to COVID-19 conspiracy theories

Recommended

Clinical

New study explores test that can detect Alzheimer’s years before diagnosis

1 Min Read
Health

New research explores the association between viral infection and Alzheimer’s disease

1 Min Read
Clinical

Prenatal exposure to pollution may be linked to lower cognitive scores in infants

1 Min Read
Clinical

Researchers unveil new drug candidate to help treat adrenoleukodystrophy

1 Min Read
//

We are a trusted online source for research news and resources on all aspects of the mind and human behavior.

Verticals

  • Clinical
  • Health
  • Social
  • I/O
  • Opinion

Social

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Links

  • About
  • Contact
  • The Editor
  • Terms & Conditions
  • Privacy Policy
Follow US

© 2022 Mental Daily. All Rights Reserved.

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?